Literature DB >> 20044005

A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy.

Sarah A Eisenstein1, Jason R Clapper, Philip V Holmes, Daniele Piomelli, Andrea G Hohmann.   

Abstract

Bilateral olfactory bulbectomy (OBX) in rodents produces behavioral and neurochemical changes associated clinically with depression and schizophrenia. Most notably, OBX induces hyperlocomotion in response to the stress of exposure to a novel environment. We examined the role of the endocannabinoid system in regulating this locomotor response in OBX and sham-operated rats. In our study, OBX-induced hyperactivity was restricted to the first 3 min of the open field test, demonstrating the presence of novelty (0-3 min) and habituation (3-30 min) phases of the open field locomotor response. Levels of the endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide were decreased in the ventral striatum, a brain region deafferented by OBX, whereas cannabinoid receptor densities were unaltered. In sham-operated rats, 2-AG levels in the ventral striatum were negatively correlated with distance traveled during the novelty phase. Thus, low levels of 2-AG are reflected in a hyperactive open field response. This correlation was not observed in OBX rats. Conversely, 2-AG levels in endocannabinoid-compromised OBX rats correlated with distance traveled during the habituation phase. In OBX rats, pharmacological blockade of cannabinoid CB(1) receptors with either AM251 (1 mg kg(-1) i.p.) or rimonabant (1 mg kg(-1) i.p.) increased distance traveled during the habituation phase. Thus, blockade of endocannabinoid signaling impairs habituation of the hyperlocomotor response in OBX, but not sham-operated, rats. By contrast, in sham-operated rats, effects of CB(1) antagonism were restricted to the novelty phase. These findings suggest that dysregulation in the endocannabinoid system, and 2-AG in particular, is implicated in the hyperactive locomotor response induced by OBX. Our studies suggest that drugs that enhance 2-AG signaling, such as 2-AG degradation inhibitors, might be useful in human brain disorders modeled by OBX. (c) 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20044005      PMCID: PMC2867105          DOI: 10.1016/j.phrs.2009.12.013

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  67 in total

1.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 2.  The role of dopamine-dependent negative feedback in the hippocampus-basal ganglia-thalamus-hippocampus loop in the extinction of responses.

Authors:  I G Sil'kis
Journal:  Neurosci Behav Physiol       Date:  2008-05

Review 3.  Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders.

Authors:  Boris B Gorzalka; Matthew N Hill; Cecilia J Hillard
Journal:  Neurosci Biobehav Rev       Date:  2008-03-18       Impact factor: 8.989

4.  The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization.

Authors:  Gunnar Thiemann; Mario van der Stelt; Stefania Petrosino; Areles Molleman; Vincenzo Di Marzo; Rüdiger U Hasenöhrl
Journal:  Behav Brain Res       Date:  2007-09-25       Impact factor: 3.332

5.  Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression.

Authors:  Emmanuel S Onaivi; Hiroki Ishiguro; Jian-Ping Gong; Sejal Patel; Paul A Meozzi; Lester Myers; Alex Perchuk; Zoila Mora; Patricia A Tagliaferro; Eileen Gardner; Alicia Brusco; B Emmanuel Akinshola; Qing-Rong Liu; Sanika S Chirwa; Bruce Hope; Javier Lujilde; Toshiya Inada; Shinya Iwasaki; David Macharia; Lindsey Teasenfitz; Tadao Arinami; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

6.  The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus.

Authors:  Gunnar Thiemann; Vincenzo Di Marzo; Areles Molleman; Rüdiger U Hasenöhrl
Journal:  Pharmacol Biochem Behav       Date:  2008-01-26       Impact factor: 3.533

7.  Activation of endocannabinoid transmission induces antidepressant-like effects in rats.

Authors:  P Adamczyk; A Gołda; A C McCreary; M Filip; E Przegaliński
Journal:  J Physiol Pharmacol       Date:  2008-06       Impact factor: 3.011

Review 8.  Glutamate-dopamine-GABA interactions in the aging basal ganglia.

Authors:  Francisco Mora; Gregorio Segovia; Alberto Del Arco
Journal:  Brain Res Rev       Date:  2007-10-26

9.  Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity.

Authors:  Louise Adermark; Giuseppe Talani; David M Lovinger
Journal:  Eur J Neurosci       Date:  2009-01       Impact factor: 3.386

Review 10.  Endocannabinoid signaling as a synaptic circuit breaker in neurological disease.

Authors:  István Katona; Tamás F Freund
Journal:  Nat Med       Date:  2008-09-05       Impact factor: 53.440

View more
  14 in total

1.  Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation.

Authors:  E Zamberletti; F Piscitelli; F Cadeddu; T Rubino; W Fratta; P Fadda; V Di Marzo; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

2.  Antidepressant Effects of Ketamine Are Not Related to ¹⁸F-FDG Metabolism or Tyrosine Hydroxylase Immunoreactivity in the Ventral Tegmental Area of Wistar Rats.

Authors:  Pedro Porto Alegre Baptista; Lisiani Saur; Pamela Bambrilla Bagatini; Samuel Greggio; Gianina Teribele Venturin; Sabrina Pereira Vaz; Kelly Dos Reis Ferreira; Juliana Silva Junqueira; Diogo Rizzato Lara; Jaderson Costa DaCosta; Cristina Maria Moriguchi Jeckel; Régis Gemerasca Mestriner; Léder Leal Xavier
Journal:  Neurochem Res       Date:  2015-04-17       Impact factor: 3.996

3.  Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats.

Authors:  Natale R Sciolino; Wenyi Zhou; Andrea G Hohmann
Journal:  Pharmacol Res       Date:  2011-05-11       Impact factor: 7.658

Review 4.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

5.  Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling.

Authors:  Peng Zhong; Wei Wang; Bin Pan; Xiaojie Liu; Zhen Zhang; Jonathan Z Long; Han-ting Zhang; Benjamin F Cravatt; Qing-song Liu
Journal:  Neuropsychopharmacology       Date:  2014-01-30       Impact factor: 7.853

Review 6.  Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability.

Authors:  Hu Wang; Tin Oo Khor; Limin Shu; Zheng-Yuan Su; Francisco Fuentes; Jong-Hun Lee; Ah-Ng Tony Kong
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

7.  Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli.

Authors:  Daniela Laricchiuta; Alessandra Musella; Silvia Rossi; Diego Centonze
Journal:  Front Behav Neurosci       Date:  2014-05-19       Impact factor: 3.558

8.  The endocannabinoid/endovanilloid system and depression.

Authors:  Irena Smaga; Beata Bystrowska; Dawid Gawliński; Edmund Przegaliński; Małgorzata Filip
Journal:  Curr Neuropharmacol       Date:  2014-09       Impact factor: 7.363

Review 9.  Endocannabinoid-mediated neuromodulation in the main olfactory bulb at the interface of environmental stimuli and central neural processing.

Authors:  Thomas Heinbockel; Naina Bhatia-Dey; Vonnie D C Shields
Journal:  Eur J Neurosci       Date:  2021-04-02       Impact factor: 3.698

10.  Long-term effect of uncomplicated Plasmodium berghei ANKA malaria on memory and anxiety-like behaviour in C57BL/6 mice.

Authors:  Luciana Pereira de Sousa; Roberto Farina de Almeida; Flávia Lima Ribeiro-Gomes; Leonardo José de Moura Carvalho; Tadeu Mello E Souza; Diogo Onofre Gomes de Souza; Cláudio Tadeu Daniel-Ribeiro
Journal:  Parasit Vectors       Date:  2018-03-20       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.